Actuate Therapeutics, Inc./$ACTU
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Actuate Therapeutics, Inc.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
- Ticker
- $ACTU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Fort Worth, United States
- Website
- actuatetherapeutics.com
ACTU Metrics
BasicAdvanced
$17M
-
-$0.89
0.78
-
Price and volume
Market cap
$17M
Beta
0.78
52-week high
$7.90
52-week low
$0.29
Average daily volume
467K
Financial strength
Current ratio
1.248
Quick ratio
1.163
Interest coverage (TTM)
-1,025.85%
Profitability
Management effectiveness
Return on assets (TTM)
-213.40%
Return on equity (TTM)
2,457.58%
Valuation
Price to book
7.34
Price to tangible book (TTM)
7.34
Price to free cash flow (TTM)
-0.352
Free cash flow yield (TTM)
-284.30%
Free cash flow per share (TTM)
-0.859
Growth
Earnings per share change (TTM)
-37.61%
ACTU Financial Performance
Revenues and expenses
ACTU Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.